Xeris Pharmaceuticals Inc (XERS) Stock Price, Quote & News

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 445 5704

Website: www.xerispharma.com

Address:

1375 West Fulton Street, Suite 1300, Chicago, United States

Universaal Feb. 3 at 11:23 PM

$XERS does Amgn earnings matter? They beat though

0 · Reply

LurkerBoy Feb. 3 at 10:15 PM

$XERS Dead fish for months.

0 · Reply

BuyThisOne Feb. 3 at 9:42 PM

$XERS Followed the XBI today like a shadow. Steady we will continue to rise over the years and we will eventually cast a large shadow. From a $1 to here we have handily beat the market since 2023. I wish my average was closer to $1 but low $2's is still way better than the overall market. Q4 earnings is coming up fast. Feels like we just had the Q3 call and then May will be here in a flash as well.

0 · Reply

Al43075 Feb. 3 at 5:08 PM

$XERS will gvoke vial dx sales be included with gvoke,or listed seperately

1 · Reply

KTdad Feb. 3 at 4:45 PM

$XERS sell in the morning. Buy in the afternoon.

0 · Reply

BullMaven Feb. 3 at 3:50 PM

$XERS unique opportunity to add cheap . 10+ after Q4

0 · Reply

BuyThisOne Feb. 3 at 2:57 PM

$XERS

0 · Reply

TymeTryethTroth Feb. 3 at 2:26 PM

$XERS https://seekingalpha.com/article/4865261-xeris-biopharma-strong-recorlev-momentum-and-pipeline-opportunity?share_source=shared_news $BMRN $RARE $LLY $CORT (Comps mentioned in article)

0 · Reply

Finwizard61 Feb. 3 at 2:23 PM

$XERS Excellent SA article on Xeris!

0 · Reply

Aptos2020 Feb. 3 at 1:21 PM

$XERS Sonnier!

0 · Reply

Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity

Jan 8, 2026, 7:00 AM EST - 26 days ago

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Jan 2, 2026, 4:15 PM EST - 4 weeks ago

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 1, 2025, 7:00 AM EST - 2 months ago

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Nov 6, 2025, 11:16 AM EST - 3 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 3 months ago

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Oct 23, 2025, 7:30 AM EDT - 3 months ago

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 3, 2025, 4:15 PM EDT - 4 months ago

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2025, 10:03 AM EDT - 5 months ago

Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy

Aug 25, 2025, 7:00 AM EDT - 5 months ago

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Aug 7, 2025, 7:38 PM EDT - 6 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 6 months ago

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 18, 2025, 10:17 AM EDT - 8 months ago

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

Jun 3, 2025, 7:30 AM EDT - 8 months ago

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 9 months ago

Xeris Announces Details for Analyst & Investor Day

May 8, 2025, 2:15 PM EDT - 9 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 9 months ago

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 7, 2025, 11:51 AM EDT - 9 months ago

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 1, 2025, 7:00 AM EDT - 9 months ago

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 28, 2025, 8:00 AM EDT - 11 months ago

Xeris Announces Changes to Its Board of Directors

Mar 17, 2025, 8:00 AM EDT - 11 months ago

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Mar 6, 2025, 10:52 AM EST - 11 months ago

Xeris Biopharma Holdings, Inc. (XERS) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 11 months ago

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Feb 27, 2025, 7:00 AM EST - 1 year ago

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Feb 24, 2025, 8:00 AM EST - 1 year ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 5, 2025, 8:00 AM EST - 1 year ago

Xeris to Participate in Upcoming Investor Conferences

Jan 21, 2025, 9:00 AM EST - 1 year ago

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Jan 10, 2025, 7:00 AM EST - 1 year ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 6, 2025, 4:15 PM EST - 1 year ago

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 8, 2024, 11:50 AM EST - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Oct 25, 2024, 12:50 PM EDT - 1 year ago

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 11, 2024, 2:00 PM EDT - 1 year ago

Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +

GNRC KLC PHG

Oct 9, 2024, 11:33 AM EDT - 1 year ago

Xeris Biopharma: Time For A Reassessment

Aug 8, 2024, 11:56 AM EDT - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Jul 25, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Announces CEO Succession Plan

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

May 30, 2024, 7:30 AM EDT - 1 year ago

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

May 30, 2024, 7:00 AM EDT - 1 year ago

Xeris to Participate in the Jefferies Global Healthcare Conference

May 9, 2024, 12:49 PM EDT - 1 year ago

Xeris Biopharma Holdings, Inc. (XERS) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

May 6, 2024, 7:00 AM EDT - 1 year ago

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

May 2, 2024, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 30, 2024, 1:28 AM EDT - 2 years ago

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Universaal Feb. 3 at 11:23 PM

$XERS does Amgn earnings matter? They beat though

0 · Reply

LurkerBoy Feb. 3 at 10:15 PM

$XERS Dead fish for months.

0 · Reply

BuyThisOne Feb. 3 at 9:42 PM

0 · Reply

Al43075 Feb. 3 at 5:08 PM

$XERS will gvoke vial dx sales be included with gvoke,or listed seperately

1 · Reply

KTdad Feb. 3 at 4:45 PM

$XERS sell in the morning. Buy in the afternoon.

0 · Reply

BullMaven Feb. 3 at 3:50 PM

$XERS unique opportunity to add cheap . 10+ after Q4

0 · Reply

BuyThisOne Feb. 3 at 2:57 PM

$XERS

0 · Reply

TymeTryethTroth Feb. 3 at 2:26 PM

$XERS https://seekingalpha.com/article/4865261-xeris-biopharma-strong-recorlev-momentum-and-pipeline-opportunity?share_source=shared_news $BMRN $RARE $LLY $CORT (Comps mentioned in article)

0 · Reply

Finwizard61 Feb. 3 at 2:23 PM

$XERS Excellent SA article on Xeris!

0 · Reply

Aptos2020 Feb. 3 at 1:21 PM

$XERS Sonnier!

0 · Reply

Savvy7 Feb. 3 at 12:48 PM

$XERS 3 months pounding sand. I see the long term trend is still in tact. And I believe the next move is higher, but get on with it!

0 · Reply

xersdave Feb. 3 at 9:44 AM

$XERS Super Conservative Outlook Long term HOLD Gvoke 100m Keyvesis 50m Recorlev 350m (1361 patients) LEVO 500m (only 5% enrollment = 200k out of 4 million patients) _____________________________ 1 Billion Revenue @ 85% margin

0 · Reply

Universaal Feb. 3 at 3:17 AM

$XERS what are those Form 4 filings insider sold off ??

1 · Reply

Night_Owl_Biotech Feb. 3 at 12:55 AM

The attached table notes the day of the week all 82 commercial-stage oncology (26) & non-oncology (56) bio M&A transactions were announced (those bios with 1st FDA approvals since 1/1/2013 so you won't see SGEN nor CELG for example). Roughly half of these M&A exits are announced on Mondays. In oncology its 62% of the time. Wednesday is the next most popular day of the week to announce acquisitions in this peer group. We track the dates M&A transactions are announced manually & use the "WEEKDAY" tool in excel to extrapolate the day of the week. In the past, we misread the "WEEKDAY" result by assuming 2 represented Tuesdays. Hence until we re-ran this analysis we thought Tuesdays were the most popular day to announce M&A trxs. We're going to run the same for clinical-stage bio M&A exits in the next few days. Our educated guesses of strong M&A candidates include: $SNDX $ARWR $CYTK $VKTX $XERS This is not investment advice. We're only sharing our analysis for entertainment purposes only.

0 · Reply

Johnny_Fever Feb. 2 at 6:57 PM

$XERS

0 · Reply

Invest0r_Gadget Feb. 2 at 6:24 PM

$XERS $20.26

0 · Reply

Al43075 Feb. 2 at 5:55 PM

$XERS last chance at this price

1 · Reply

n9zro Feb. 2 at 3:25 PM

$XERS Hey @Sam_Cutcher How ya doing Buddy ?

1 · Reply

simonig1 Feb. 2 at 3:11 PM

$XERS The chart below shows that XERS has again bounced off the bottom of the uptrend channel and this morning has gone above the 21 day EMA (and also the 8 day EMA). As the 8 day EMA (gray dots) goes above the 21 day EMA (thick red line) there could be a surge in price. Enjoy!!!

0 · Reply

Finwizard61 Feb. 2 at 3:05 PM

$XERS Picked up 1,000 shares… at $7.50! Supremely confident we will hit $8.00 soon.. 🔜

0 · Reply

pascallambrecht Feb. 2 at 2:56 PM

$XERS we need rebound 8/10 dollar ..

0 · Reply

Finwizard61 Feb. 2 at 2:47 PM

$XERS Time to add a few hundred shares. This is the day to add folks.. Xeris moving up on only a few hundred shares on the buy side…

0 · Reply

Market Cap	1.22B
Revenue (ttm)	203.07M
Net Income (ttm)	-54.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	30.81
Profit Margin	-27.01%
Debt to Equity Ratio	-255.20

Volume	1,329,700
Avg Vol	2,090,492
Day's Range	N/A - N/A
Shares Out	165.92M
Stochastic %K	39%
Beta	0.50
Analysts	Strong Sell
Price Target	$11.14